| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2023―Mar―17 |
A Significant Difference in Core PDZ Interactivity of SARS-CoV, SARS-CoV2 and MERS-CoV Protein E Peptide PDZ Motifs In Vitro |
Martina Baliova, Iveta Jahodova, Frantisek Jursky |
| 2 |
[GO] |
2022―Sep―01 |
Biophysical and Biochemical Characterization of the Receptor Binding Domain of SARS-CoV-2 Variants |
Ritika Khatri, Hilal Ahmad Parray, Gazala Siddiqui, Adarsh Kumar Chiranjivi, Sneha Raj, Rachel Kaul, Vikas Maithil, Sweety Samal, Shubbir Ahmed |
| 3 |
[GO] |
2022―Aug―01 |
Evolution of Stronger SARS-CoV-2 Variants as Revealed Through the Lens of Molecular Dynamics Simulations |
Alec J. Wozney, Macey A. Smith, Mobeen Abdrabbo, Cole M. Birch, Kelsey A. Cicigoi, Connor C. Dolan, Audrey E. L. Gerzema, Abby Hansen, Ethan J. Henseler, Ben LaBerge, Caterra M. Leavens, Christine N. Le, Allison C. Lindquist, Rikaela K. Ludwig, Maggie G. O’Reilly, Jacob H. Reynolds, Brandon A. Sherman, Hunter W. Sillman, Michael A. Smith, Marissa J. Snortheim, Levi M. Svaren, Emily C. Vanderpas, Aidan Voon, Miles J. Wackett, Moriah M. Weiss, Sanchita Hati, Sudeep Bhattacharyya |
| 4 |
[GO] |
2021―Sep―09 |
Bioactive Molecules Derived from Snake Venoms with Therapeutic Potential for the Treatment of Thrombo-Cardiovascular Disorders Associated with COVID-19 |
Fatah Chérifi, Fatima Laraba-Djebari |
| 5 |
[GO] |
2021―May―21 |
Update and Supplementary Articles Proteins of SARS CoV-2, Which Causes COVID-19, and the Interacting Proteins |
Francis K. Yoshimoto, Lawrence J. Berliner |
| 6 |
[GO] |
2021―Apr―22 |
In Silico Study of Mutational Stability of SARS-CoV-2 Proteins |
Dwaipayan Chaudhuri, Satyabrata Majumder, Joyeeta Datta, Kalyan Giri |
| 7 |
[GO] |
2021―Apr―11 |
Milk Peptides as Novel Multi-Targeted Therapeutic Candidates for SARS-CoV2 |
H. Pradeep, Umme Najma, H. S. Aparna |
| 8 |
[GO] |
2021―Jan―15 |
The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19 |
Francis K. Yoshimoto |
| 9 |
[GO] |
2021―Jan―15 |
Perspective on the Role of Antibodies and Potential Therapeutic Drugs to Combat COVID-19 |
Siddhi Tandon, Anchal Aggarwal, Shubhra Jain, Sanjay Shukla, Sarika Chaudhary |
| 10 |
[GO] |
2021―Jan―15 |
Editorial: Proteins of SARS CoV-2, the Cause of COVID-19, and the Proteins that Interact with Them |
Francis K. Yoshimoto, Lawrence J. Berliner |
| 11 |
[GO] |
2021―Jan―15 |
Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review |
Shanzay Suhail, Jonathan Zajac, Carl Fossum, Harrison Lowater, Cailin McCracken, Nathaniel Severson, Bethany Laatsch, Alex Narkiewicz-Jodko, Benjamin Johnson, Jessica Liebau, Sudeep Bhattacharyya, Sanchita Hati |
| 12 |
[GO] |
2021―Jan―15 |
Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment |
Lindsey S Jung, Tamara M Gund, Mahesh Narayan |
| 13 |
[GO] |
2021―Jan―15 |
An Overview of the Crystallized Structures of the SARS-CoV-2 |
Mihaela Ileana Ionescu |
| 14 |
[GO] |
2021―Jan―15 |
In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors |
Mahmoud A. A. Ibrahim, Alaa H. M. Abdelrahman, Khaled S. Allemailem, Ahmad Almatroudi, Mahmoud F. Moustafa, Mohamed-Elamir F. Hegazy |
|
